National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 6 of 2000)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, aims to establish a comprehensive health service system in Australia. One of the gaps it addresses is the regulation and management of pharmaceuticals, particularly those listed under the Pharmaceutical Benefits Scheme (PBS). The Act facilitates the provision of affordable and accessible medications to the Australian public. The Pharmaceutical Benefits Declaration under subsection 85 (2AA) of the Act, made by Brett Anthony Lennon, Assistant Secretary of the Pharmaceutical Benefits Branch, Department of Health and Aged Care, and acting as the delegate of the Minister for Health and Aged Care, specifies that certain drugs and medicinal preparations will cease to be covered under the PBS. This legislative instrument, numbered PB 6 of 2000, came into effect on 1 May 2000 and identifies Erythromycin Estolate as the drug to be removed from the PBS schedule. The policy objective underlying this declaration is to ensure the PBS remains effective and aligned with current medical standards and evidence-based practices.

Scope and Application

The National Health Act 1953 applies to the regulation of pharmaceuticals in Australia, with specific provisions concerning the Pharmaceutical Benefits Scheme (PBS). The Act applies to persons, entities, and industries involved in the supply and prescription of pharmaceutical benefits, including doctors, pharmacists, and pharmaceutical companies. The geographic reach of the Act is national, as it is a Commonwealth statute, applying across all states and territories of Australia. The Act, through subordinate instruments such as the declaration under subsection 85(2AA), can specify particular drugs and medicinal preparations that are subject to or excluded from the provisions of Part VII. This particular legislative instrument specifies that Erythromycin Estolate will cease to be covered under the PBS from the effective date of 1 May 2000, following the advice of the Pharmaceutical Benefits Advisory Committee. The exclusion of certain drugs from the PBS can be further refined or expanded through additional declarations or legislative amendments, thereby extending or restricting the application of the Act.

Key Provisions

The Declaration under subsection 85 (2AA) of the National Health Act 1953, made by Brett Anthony Lennon, Assistant Secretary of the Pharmaceutical Benefits Branch, Department of Health and Aged Care, specifies that the drug Erythromycin Estolate will cease to be subject to Part VII of the Act. This part of the Act pertains to the pharmaceutical benefits scheme, which is the framework through which the Commonwealth subsidises the cost of certain prescription medicines for Australian residents. Section 85 (2AA) allows the Minister for Health and Aged Care, or their delegate, to declare that certain drugs will no longer be covered by the scheme, following advice from the Pharmaceutical Benefits Advisory Committee. This particular declaration was made effective from 1 May 2000, as indicated in section 2. Under this Act, entities such as pharmaceutical companies, healthcare providers, and patients who would have previously been entitled to a subsidy for Erythromycin Estolate under the pharmaceutical benefits scheme will no longer be eligible for such a subsidy. This change means that from the effective date of the declaration, the cost of Erythromycin Estolate will no longer be subsidised by the Commonwealth, and patients will have to bear the full cost of the medication unless they have private health insurance that covers this drug. In terms of legal obligations, the declaration imposes a clear directive that Erythromycin Estolate is excluded from the list of medicines covered by the pharmaceutical benefits scheme. This exclusion is binding on all parties involved, including the Commonwealth, state and territory governments, healthcare providers, and patients. Pharmaceutical companies must adjust their pricing and billing practices accordingly, and healthcare providers must inform patients of the change in subsidy status. Breaching the provisions of this declaration could lead to civil or criminal penalties, although the specific offences and penalties are not detailed in the text provided. Typically, under the National Health Act 1953, non-compliance with the provisions regarding the pharmaceutical benefits scheme could result in fines or other legal repercussions. However, the precise nature and extent of these penalties would depend on the specifics of the breach and would be subject to the broader provisions of the Act and any relevant regulations.